IPP Bureau
AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
By IPP Bureau - October 31, 2025
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
By IPP Bureau - October 31, 2025
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat
By IPP Bureau - October 31, 2025
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics
By IPP Bureau - October 31, 2025
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
By IPP Bureau - October 31, 2025
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness
By IPP Bureau - October 31, 2025
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions
By IPP Bureau - October 31, 2025
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
RestorixHealth acquires CutisCare to expands wound care portfolio
By IPP Bureau - October 31, 2025
Lupin Digital Health launches VITALYFE
By IPP Bureau - October 31, 2025
AI-powered cardiometabolic wellness platform for India’s workforce
NATCO launches Everolimus tablets, 1 mg
By IPP Bureau - October 31, 2025
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
By IPP Bureau - October 30, 2025
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Granules India’s facility secures FDA EIR with 'VAI’
By IPP Bureau - October 30, 2025
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
By IPP Bureau - October 30, 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
